Radiolabeled anti–prostate-specific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castration-resistant prostate cancer (CRPC).

Management expects typical Q3 to Q4 operating ratio degradation to be in the "300 to 400 basis point" range, with Batteh noting, "With October trending a little bit lower this year than what we've ...

Simplify the Company’s existing plant network and streamline its operating structure by consolidating volume into a smaller number of facilities, which is expected to lower costs and improve margins; ...

Impact of interstitial brachytherapy (IB) or radical prostatectomy (RP) on quality of life (QL) of patients (pts) treated for localized prostate cancer (LPC): Medium-term outcomes from a prospective ...

HANOVER, Pa.--(BUSINESS WIRE)--Utz Brands, Inc. (NYSE: UTZ) and its affiliated entities (“Utz” or the “Company”), a leading U.S. manufacturer of branded salty snacks, today announced several network ...